HOUSTON--(BUSINESS WIRE)--Pharm-Olam International LLC, a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Julia Graz as Senior Director, Biostatistics.
Ms. Graz adds over 25 years of progressive pharmaceutical industry experience to the Pharm-Olam team. Her interests and specialties are varied and well-tested. She has worked in biostatistics, programming, data management, pharmacokinetics and quality control. Her multidisciplinary experience spans dozens of pre-clinical and Phase I-IV clinical trials.
“Biostatistics is a key component of our full-service offering,” said Sanjiv Suri, Chief Executive Officer, Pharm-Olam International. “That’s why Julia is such a great addition. Her record is enviable and formidable. I’m confident she’ll be successful in helping us further develop our strategy, create efficiencies, and expand our Biostatistics business unit.”
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials. More information about Pharm-Olam and its full-service capabilities and offerings are available at www.Pharm-Olam.com, or by request via email (info@pharm-olam.com).
About Pharm-Olam International Group
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™.
For more information about Pharm-Olam, visit www.Pharm-Olam.com.
